NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Receives $8.50 Average Price Target from Analysts

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) has been assigned an average recommendation of “Moderate Buy” from the five ratings firms that are presently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, two have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $8.50.

Several brokerages have recently commented on NRSN. Weiss Ratings reiterated a “sell (d-)” rating on shares of NeuroSense Therapeutics in a report on Friday, May 8th. D. Boral Capital reiterated a “buy” rating and issued a $14.00 target price on shares of NeuroSense Therapeutics in a report on Wednesday, April 8th. Finally, Roth Mkm initiated coverage on shares of NeuroSense Therapeutics in a report on Tuesday, March 10th. They issued a “buy” rating and a $3.00 target price for the company.

NeuroSense Therapeutics Price Performance

Shares of NRSN stock opened at $0.76 on Thursday. The firm has a 50-day moving average of $0.78 and a 200-day moving average of $0.84. The company has a market cap of $24.75 million, a P/E ratio of -1.41 and a beta of 1.56. NeuroSense Therapeutics has a one year low of $0.63 and a one year high of $2.28.

Insider Transactions at NeuroSense Therapeutics

In other news, CEO Alon Ben-Noon purchased 250,000 shares of the business’s stock in a transaction dated Tuesday, June 16th. The stock was bought at an average price of $0.80 per share, for a total transaction of $200,000.00. Following the purchase, the chief executive officer owned 4,534,233 shares of the company’s stock, valued at $3,627,386.40. The trade was a 5.84% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Or Eisenberg bought 250,000 shares of the business’s stock in a transaction on Tuesday, June 16th. The shares were acquired at an average price of $0.80 per share, with a total value of $200,000.00. Following the transaction, the chief financial officer directly owned 1,504,050 shares of the company’s stock, valued at approximately $1,203,240. This trade represents a 19.94% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Company insiders own 27.40% of the company’s stock.

Institutional Trading of NeuroSense Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the business. Yorkville Advisors Global LP bought a new stake in shares of NeuroSense Therapeutics in the fourth quarter valued at approximately $77,000. Two Sigma Investments LP bought a new stake in shares of NeuroSense Therapeutics in the third quarter valued at approximately $26,000. Squarepoint Ops LLC grew its position in shares of NeuroSense Therapeutics by 91.0% in the third quarter. Squarepoint Ops LLC now owns 95,375 shares of the company’s stock valued at $119,000 after purchasing an additional 45,450 shares in the last quarter. Finally, Jane Street Group LLC purchased a new position in shares of NeuroSense Therapeutics in the second quarter valued at $54,000. Institutional investors own 1.04% of the company’s stock.

About NeuroSense Therapeutics

NeuroSense Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative and age-related neurological disorders. The company’s primary mission is to address unmet medical needs in diseases characterized by protein aggregation, chronic inflammation and cellular senescence in the central nervous system.

At the core of NeuroSense’s approach is a proprietary senotherapeutic platform designed to selectively target and clear senescent cells that contribute to neurodegeneration.